Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?

Tuna G, Küçükhüseyin O, Arıkan S, Kaytan Sağlam E, Güler E, Cacına C, Oztop O, Turan S, Korkmaz G, Yaylım I.

DNA Cell Biol. 2013 Jul;32(7):400-8. doi: 10.1089/dna.2012.1933. Epub 2013 Jun 18.

PMID:
23777425
2.

Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.

Kafadar A, Küçükhüseyin Ö, Turan S, Yenilmez EN, Tunoglu S, Zeybek U, Kaynar MY, Kemerdere R, Yaylim I.

Anticancer Res. 2015 Jul;35(7):3933-42.

PMID:
26124340
3.

MDM2 SNP309 polymorphism is associated with colorectal cancer risk.

Wang W, Du M, Gu D, Zhu L, Chu H, Tong N, Zhang Z, Xu Z, Wang M.

Sci Rep. 2014 May 6;4:4851. doi: 10.1038/srep04851.

4.

Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.

Zhang X, Pageon L, Post SM.

Oncogene. 2015 Aug 13;34(33):4412-20. doi: 10.1038/onc.2014.377. Epub 2014 Dec 1.

PMID:
25435368
5.

Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.

Fu Q, Zhang G, Chen H, Zheng Y, Cheng J.

Tumour Biol. 2013 Dec;34(6):3721-9. doi: 10.1007/s13277-013-0956-z. Epub 2013 Aug 3.

PMID:
23912932
6.
7.

TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.

Abderrahmane R, Louhibi L, Moghtit FZ, Boubekeur A, Benseddik K, Boudjema A, Benrrahal F, Aberkane M, Fodil M, Saidi-Mehtar N.

Pathol Oncol Res. 2015 Jul;21(3):629-35. doi: 10.1007/s12253-014-9867-6. Epub 2014 Dec 24.

PMID:
25537146
8.

Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

Walsh CS, Miller CW, Karlan BY, Koeffler HP.

Gynecol Oncol. 2007 Mar;104(3):660-4. Epub 2006 Nov 21.

PMID:
17123590
9.

MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.

Dong HJ, Fang C, Fan L, Zhu DX, Wang DM, Zhu HY, Zhuang Y, Miao KR, Liu P, Xu W, Li JY.

Int J Cancer. 2012 May 1;130(9):2054-61. doi: 10.1002/ijc.26222. Epub 2011 Aug 9.

10.

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.

Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T, Wake N.

Oncol Rep. 2013 Jul;30(1):25-34. doi: 10.3892/or.2013.2433. Epub 2013 Apr 29.

11.

[Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].

Liu JN, Zhang XM, Guo YL, Sun T, Lin DX, Wen T.

Zhonghua Zhong Liu Za Zhi. 2008 May;30(5):335-8. Chinese.

PMID:
18953830
12.

Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.

Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC, Lee YJ.

Oncol Rep. 2011 Jun;25(6):1755-63. doi: 10.3892/or.2011.1254. Epub 2011 Apr 8.

PMID:
21479369
13.

Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.

Zając A, Stachowiak G, Pertyński T, Romanowicz H, Wilczyński J, Smolarz B.

Pol J Pathol. 2012 Dec;63(4):278-83.

14.

Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.

Hitzenbichler F, Stoehr CG, Rogenhofer M, Wieland WF, Ruemmele P, Hartmann A, Stoehr R.

Pathobiology. 2014;81(2):53-9. doi: 10.1159/000355976. Epub 2013 Nov 9.

PMID:
24217660
15.

MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.

Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Lee CP, Lin SF.

Mol Carcinog. 2014 Dec;53(12):951-9. doi: 10.1002/mc.22061. Epub 2013 Jul 2.

PMID:
23818300
16.

Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Yu H, Huang YJ, Liu Z, Wang LE, Li G, Sturgis EM, Johnson DG, Wei Q.

Mol Carcinog. 2011 Sep;50(9):697-706. doi: 10.1002/mc.20806. Epub 2011 Jun 7.

17.

An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.

Qin X, Peng Q, Tang W, Lao X, Chen Z, Lai H, Deng Y, Mo C, Sui J, Wu J, Zhai L, Yang S, Li S, Zhao J.

PLoS One. 2013 Sep 30;8(9):e76031. doi: 10.1371/journal.pone.0076031. eCollection 2013.

18.

p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome.

Sotamaa K, Liyanarachchi S, Mecklin JP, Järvinen H, Aaltonen LA, Peltomäki P, de la Chapelle A.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6840-4.

19.

MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.

Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ.

Breast Cancer Res Treat. 2008 Oct;111(3):497-504. Epub 2007 Nov 18.

PMID:
18026875
20.

Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study.

Assmann G, Voswinkel J, Mueller M, Bittenbring J, Koenig J, Menzel A, Pfreundschuh M, Roemer K, Melchers I.

Clin Exp Rheumatol. 2009 Jul-Aug;27(4):615-9.

PMID:
19772793
Items per page

Supplemental Content

Write to the Help Desk